Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals, Inc (RXRX)
:RXRX
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.52Last Year’s EPS
-0.39Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 28, 2025
|% Change Since: -19.56%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong year for Recursion with significant advancements in clinical programs, partnerships, and technology infrastructure. Financially, the company is well-positioned with a strong cash balance, despite some revenue recognition challenges. The overall sentiment is positive due to the substantial achievements outweighing the noted challenges.Company Guidance
During the earnings call, Recursion's leadership provided extensive guidance on their achievements and future plans, highlighting numerous metrics. In 2024, Recursion reported $83 million in revenue on a pro forma basis and ended the year with over $600 million in cash, providing a runway extending into 2027. They achieved $45 million in cash payments from milestone achievements with partners Sanofi and Roche and generated $15 million in aggregate payments from advancing two programs with Sanofi. Their supercomputer, BioHive-2, has been fully operational, processing up to 6.2 million multi-timepoint brightfield images weekly and generating nearly one million transcriptomes in 2024. The company aims to achieve $100 million in synergies from their merger, with expectations of realizing a majority of these in the current year. Additionally, Recursion's long-term strategy includes developing virtual cells, leveraging multi-modal data, and refining their platform capabilities, which they claim will lead to faster and more efficient drug discovery and development processes.Early Clinical Successes
REC-617 showed early signals of efficacy in monotherapy during the dose escalation phase, with one patient having sustained tumor reduction for over six months. REC-994 demonstrated robust chronic safety and encouraging reduction in lesion size in Phase II study.
Strong Pipeline Expansion
Multiple trials were launched, including REC-1245 for RBM39 degradation in solid tumors, REK-4881 for familial adenomatous polyposis, and REC-3964 for C. difficile.
Significant Partnerships and Milestone Achievements
Partnerships with Roche and Sanofi led to $30 million and $15 million in milestone payments, respectively, with continued advancements in oncology and neuroscience.
Advanced Data and Compute Developments
Launched BioHive-2 with NVIDIA, the most powerful supercomputer wholly-owned by a biopharma company, and mapped over 1.4 million active ligands for drug discovery.
Strong Financial Position
Achieved $83 million in revenue with a cash balance of over $600 million, extending the runway into 2027.
---
RXRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RXRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 28, 2025 | $7.67 | $7.51 | -2.09% |
| Nov 06, 2024 | $6.97 | $6.93 | -0.57% |
| Aug 08, 2024 | $6.37 | $6.64 | +4.24% |
| May 09, 2024 | $8.64 | $8.60 | -0.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Recursion Pharmaceuticals, Inc (RXRX) report earnings?
Recursion Pharmaceuticals, Inc (RXRX) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Recursion Pharmaceuticals, Inc (RXRX) earnings time?
Recursion Pharmaceuticals, Inc (RXRX) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RXRX EPS forecast?
RXRX EPS forecast for the fiscal quarter 2025 (Q1) is -0.52.
---